Pipeline
PORTFOLIO OF PRODUCT CANDIDATES
Product
ORTICUMAB (Atherosclerosis)
ORTICUMAB (psoriasis)
ORTICUMAB Lp(a)
AB-CE3
AB-JB7
AB-AH10
AB-SLP
AB-210
Research
Preclinical
Clinical
Unmet Need
Current anti-inflammatory immunomodulating drugs can effectively treat rheumatic diseases, but have serious side effects - including infections and cancers
- Orticumab is a monoclonal antibody that works differently than current inflammation treatments by targeting OxLDL, a highly specific source of inflammation
- Orticumab has been in 200+ patients and subjects with a pristine safety profile – no drug-related serious adverse events
- Since Orticumab works by a more targeted mechanism, we do not expect it to suppress the immune system and cause infection. That makes it different than other systemic treatments for inflammatory diseases
- Currently preparing for phase 2 trials in two indications 1) Plaque Psoriasis and 2) Accelerated atherosclerosis in rheumatology patients
Key Publications with Orticumab
Title
Authors
Li, S. et al
Gonclaves et al
Strom et al
Schiopu et al
Schiopu et al
Year
2013
2009
2007
2007
2004
Journal
Molecular Metabolism
Atherosclerosis
Atherosclerosis
JACC
Circulation
*Orticumab is also known as BI-204, 2D03, and MLDL1278a in publications